Phase 1 Huntington's Disease Trial, Recruiting (NCT06585449)

Phase 1 Huntington's Disease Trial, Recruiting NCT06585449 Sponsor: Alnylam Pharmaceuticals Condition: Huntington's Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06585449 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Huntingtons Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Stage 2 or early Stage 3 Huntington's disease, as measured by a specific staging system called the HD-ISS

Who may not be able to join:

You have a significant brain or nervous system condition other than Huntington's disease
Your immune system is weakened due to an infection, medical condition, or long-term medication
Your liver enzyme levels (specific proteins called ALT or AST) are higher than twice the normal range
Your kidneys are not filtering blood well enough, based on a measurement called eGFR being below a certain level (confirm with trial site)
You have taken part in another clinical trial or received an experimental treatment within the past year, or within a specific time period based on how that treatment works in the body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Alnylam Pharmaceuticals

Phone: 1-877-ALNYLAM

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06585449

Sponsor: Alnylam Pharmaceuticals

Phase: Phase 1

Status: Recruiting

Condition: Huntington's Disease

Trial contact: 1-877-ALNYLAM

More information: https://clinicaltrials.gov/study/NCT06585449

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Stage 2 or early Stage 3 Huntington's disease, as measured by a specific staging system called the HD-ISS

Who may not be able to join:

You have a significant brain or nervous system condition other than Huntington's disease
Your immune system is weakened due to an infection, medical condition, or long-term medication
Your liver enzyme levels (specific proteins called ALT or AST) are higher than twice the normal range
Your kidneys are not filtering blood well enough, based on a measurement called eGFR being below a certain level (confirm with trial site)
You have taken part in another clinical trial or received an experimental treatment within the past year, or within a specific time period based on how that treatment works in the body

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Alnylam Pharmaceuticals

Registry

ClinicalTrials.gov

Start date

14 October 2024

Est. completion

5 July 2028

Where this trial is recruiting

🇨🇦 Canada 🇩🇪 Germany 🇬🇧 United Kingdom

Primary endpoints

Frequency of Adverse Events (AEs) in the Double-blind Part of the Study; Frequency of AEs in the Open-label Part of the Study; Frequency of AEs in the OLE Part of the Study

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov